TY - JOUR
T1 - Varicella vaccination in children with chronic renal failure. A report of the Southwest Pediatric Nephrology Study Group
AU - Furth, Susan L.
AU - Hogg, Ronald J.
AU - Tarver, Joyce
AU - Moulton, Lawrence H.
AU - Chan, Christina
AU - Fivush, Barbara A.
PY - 2003/1/1
Y1 - 2003/1/1
N2 - Children with kidney disease are at risk for serious varicella-related complications. To evaluate the safety and immunogenicity of a two-dose regimen of varicella vaccine in children (aged 1-19 years) with chronic renal insufficiency and on dialysis, the Southwest Pediatric Nephrology Study Group (SPNSG) undertook an open-label, multi-center, prospective 3-year clinical trial. Ninety-six patients without history of varicella were enrolled. Fifty (mean age 4.2 years) had no detectable varicella zoster virus (VZV) antibody; 98% sero-converted after the two-dose regimen. At 1, 2, and 3 years' follow-up, all patients studied maintained VZV antibody, including 16 who received a transplant. No significant vaccine-associated adverse events were seen. One subject developed mild varicella (10-50 maculopapular lesions) 16 monthis post transplant. In multivariate regression analysis, patients vaccinated after age 6 years had VZV antibody levels 73% (95% confidence interval 33%-89%) lower than patients vaccinated before age 6 years after controlling for gender, estimated glomerular filtration rate, and dialysis treatment. Adjusted analysis also showed that VZV antibody levels were lower after kidney transplantation, but this appeared to be a transient phenomenon. In this study, varicella vaccination with a two-dose regimen of varicella vaccine was generally well tolerated and highly immunogenic in children with chronic kidney disease.
AB - Children with kidney disease are at risk for serious varicella-related complications. To evaluate the safety and immunogenicity of a two-dose regimen of varicella vaccine in children (aged 1-19 years) with chronic renal insufficiency and on dialysis, the Southwest Pediatric Nephrology Study Group (SPNSG) undertook an open-label, multi-center, prospective 3-year clinical trial. Ninety-six patients without history of varicella were enrolled. Fifty (mean age 4.2 years) had no detectable varicella zoster virus (VZV) antibody; 98% sero-converted after the two-dose regimen. At 1, 2, and 3 years' follow-up, all patients studied maintained VZV antibody, including 16 who received a transplant. No significant vaccine-associated adverse events were seen. One subject developed mild varicella (10-50 maculopapular lesions) 16 monthis post transplant. In multivariate regression analysis, patients vaccinated after age 6 years had VZV antibody levels 73% (95% confidence interval 33%-89%) lower than patients vaccinated before age 6 years after controlling for gender, estimated glomerular filtration rate, and dialysis treatment. Adjusted analysis also showed that VZV antibody levels were lower after kidney transplantation, but this appeared to be a transient phenomenon. In this study, varicella vaccination with a two-dose regimen of varicella vaccine was generally well tolerated and highly immunogenic in children with chronic kidney disease.
KW - End-stage renal disease
KW - Immunization
KW - Kidney disease
KW - Transplant
KW - Varicella
UR - http://www.scopus.com/inward/record.url?scp=0038419883&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0038419883&partnerID=8YFLogxK
U2 - 10.1007/s00467-002-1006-z
DO - 10.1007/s00467-002-1006-z
M3 - Article
C2 - 12488988
AN - SCOPUS:0038419883
SN - 0931-041X
VL - 18
SP - 33
EP - 38
JO - Pediatric Nephrology
JF - Pediatric Nephrology
IS - 1
ER -